Abstract: Provided are a method for administering a recombinant human growth hormone GX-H9 for treating growth hormone deficiency and a pharmaceutical composition containing a recombinant human growth hormone GX-H9 and a pharmaceutically acceptable carrier. The method includes administering recombinant human growth hormone GX-H9 once a week with a dosage of 0.1 to 0.3 mg per weight kg of a patient or twice-monthly with a dosage of 0.1 to 0.4 mg per weight kg of the patient.

Abstract: The present disclosure provides: a compound of a specific chemical structure, having excellent activity with respect to BTK degradation; or a pharmaceutically acceptable salt thereof. The present disclosure also provides a composition comprising the compound or pharmaceutically acceptable salts thereof. The present disclosure also provides are pharmaceutical use for treating or preventing BTK-associated diseases (for example, autoimmune diseases or cancer) of the compound, the salt thereof, and the composition comprising same according to the present disclosure. The present disclosure also provides a method for treating or preventing BTK-associated diseases (for example, autoimmune diseases or cancer), comprising administering, to a subject requiring treatment, an effective amount of the compound, the salt thereof, or the composition comprising same according to the present disclosure.

Abstract: The present invention provides a composition containing ?-lipoic acid and N-acetylcysteine as active ingredients. The mixed composition of ?-lipoic acid and N-acetylcysteine of the present invention can reduce a risk of side effects due to drugs with synergetic effects due to merge administration of two drugs, and can be usefully used for preventing or treating obesity with excellent effects of inhibiting a weight gain compared to each single composition containing ?-lipoic acid or N-acetylcysteine.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating liver diseases, containing a plasmalogen precursor, plasmalogen, or a plasmalogen analog as an effective component. More specifically, a plasmalogen precursor, or plasmalogen or a plasmalogen analog produced by metabolizing the plasmalogen precursor, can prevent or treat liver diseases such as hepatic steatosis, hepatitis, or liver cirrhosis, etc. by decreasing accumulation of neutral fats in the liver, repressing expressions of inflammatory cytokine genes, and increasing fatty acid oxidation capacity of peroxisome.

Abstract: A mobile terminal for remotely controlling and a method of remotely controlling the same that enable remote control operation of the mobile terminal by connecting a remote control device and the mobile terminal are provided. The method of remotely controlling a mobile terminal includes transmitting a key code from a remote control device by user request; receiving and recognizing the key code in the mobile terminal; converting the key code to an operation code of the mobile terminal; and controlling data output operation according to the operation code.

Abstract: A mobile terminal for remotely controlling and a method of remotely controlling the same that enable remote control operation of the mobile terminal by connecting a remote control device and the mobile terminal are provided. The method of remotely controlling a mobile terminal includes transmitting a key code from a remote control device by user request; receiving and recognizing the key code in the mobile terminal; converting the key code to an operation code of the mobile terminal; and controlling data output operation according to the operation code.